Skip to main content
. Author manuscript; available in PMC: 2022 Sep 27.
Published in final edited form as: J Biomed Nanotechnol. 2019 Nov 1;15(11):2229–2239. doi: 10.1166/jbn.2019.2859

Figure 5. CTLA-4 Nb16 increased the anti-tumor effects of CD8+ T lymphocyte by inhibiting HepG2 and MCF-7 tumor growth and enhancing survival.

Figure 5.

(A) The Therapy with DHFC+CTLA-4 Nb16 significantly delayed the tumor growth in mice bearing liver cancer xenograft. (B) Kaplan-Meier survival curves of mice reported in DHFC+CTLA-4 Nb16 group therapy significantly increased survival. (C) The Therapy with DMFC+CTLA-4 Nb16 significantly delayed the tumor growth in mice bearing breast cancer xenograft. (D) Kaplan-Meier survival curves of mice reported in DMFC+CTLA-4 Nb16 group therapy significantly increased survival. Data are means ± SD or percentage survival (n = 5 mice/group). **P < 0.01, *** P < 0.001.